Head-to-head · Value Score
Vitara RX vs Spry
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Spry a 65. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameSpry
#318 · Grade C · Watch List
Est. first month
From $199/mo (starting dose, compounded)
Save ~85% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 65 — an est. $99/mo first month, with no teaser step-up baked in. Spry isn't out of it: Shoppers who want compounded GLP-1 plus anti-aging peptides under one membership.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Spry |
|---|---|---|
| Value Score | 91 (A) | 65 (C) |
| Est. first month | $99/mo | From $199/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~85% |
| Semaglutide | $99/mo | From $199/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $299/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Spry
Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).
Why it's a deal
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
The fine print
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Spry.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.